Výsledky vyhledávání

Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer

Poly(ADP-ribose) polymerase inhibitors are FDA-approved for treatment of BRCA mutated metastatic breast cancer (MBC). Prior studies demonstrated benefit of adding oral PARPi veliparib to carboplatin and paclitaxel in BRCA mutation positive patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34457c52160e2e40c67e4aef7d3a2c79
https://doi.org/10.1101/2020.01.20.20018218

Zobrazit plný text záznamu

Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC)

Autor: Robert Wesolowski, Jun Zhang, Andrea Camp, Michael V. Knopp, Maryam B. Lustberg, Susan Ottman, Eleni Andreopoulou, Meng Zhao, Jeffrey J. Chalmers, Miguel A. Villalona-Calero, Bhuvaneswari Ramaswamy, Charles L. Shapiro, Ewa Mrozek, Nathan Hall, Rachel M. Layman, Erin Macrae Macrae, Susan Geyer, Michael R. Grever, Katharina Schregel

Publikováno v: Journal of Clinical Oncology. 32:1074-1074

1074 Background: Poly(ADP-ribose) polymerase (PARPi) inhibitors have shown activity in BRCA mutant and triple negative breast cancers (TNBC). The ideal dose and schedule of C and oral PARPi V is no...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c0f893a0aee4fc1ab40214c6319e9f9
https://doi.org/10.1200/jco.2014.32.15_suppl.1074

Zobrazit plný text záznamu

NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer

Autor: Robert Wesolowski, Jeffrey J. Chalmers, Jun Zhang, Ewa Mrozek, Michael V. Knopp, Susan Geyer, Andrea Camp, Katharina Schregel, Maryam B. Lustberg, Susan Ottman, Miguel A. Villalona-Calero, Bhuvaneswari Ramaswamy, Rachel M. Layman, Charles L. Shapiro, Erin M. Olson, Nathan Hall, Michael R. Grever

Publikováno v: Journal of Clinical Oncology. 31:1023-1023

1023 Background: We are currently conducting a phase I trial of PARP inhibitor, V on an intermittent (7 or 14 day) or continuous (21 day) schedule in combination with C in patients (pts) with advanced breast cancer. We are using FLT PET/CT sequential

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6418cab5c3bad0bf323ccb2f8e10824
https://doi.org/10.1200/jco.2013.31.15_suppl.1023

Zobrazit plný text záznamu